Search clinical trials for: BAY98-7111

Total 451 results

Bayer

Completed

A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome

Functional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia

Germany
Bayer

Completed

Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo

Irritable Bowel Syndrome

Germany
Bayer

Completed

Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function

Functional Gastrointestinal Disorders

Germany
Bayer

Completed

Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus

Functional Gastrointestinal Disorders

Germany
Bayer

Completed

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

Heart Failure

Germany
Bayer

Completed

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain (Morpheus II)

Pain, Postoperative

United States
British Columbia Cancer Agency
Canadian Cancer Society (CCS); SignalChem Lifesciences Corporation

Terminated

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01)

Metastatic Pancreatic Ductal Adenocarcinoma

Canada
Bayer

Terminated

Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients

Colitis, Ulcerative

Germany
Bayer

Completed

A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting

Functional Dyspepsia | Irritable Bowel Syndrome | Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia

Germany
Novo Nordisk A/S

Recruiting

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Obesity | Overweight

United States
Beta Pharma, Inc.

Completed

A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711

NSCLC

China
Life Molecular Imaging SA

Completed

Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

Neoplasms | Diagnostic Imaging

Korea, Republic of, United States, Germany
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

Pharmacokinetics

Germany
Bayer

Completed

A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Chronic Kidney Disease | Worsening Chronic Heart Failure

Germany
Life Molecular Imaging SA

Completed

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

Alzheimer Disease | Amyloid Beta-Protein

United States, Switzerland, Australia, Germany, Japan
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR) (ReFineDR)

Diabetic Retinopathy

Korea, Republic of, Russian Federation, Hong Kong, Taiwan, United States, Argentina, Japan, Denmark, Israel, Spain, Sweden, China, Colombia, Italy, Portugal
Life Molecular Imaging SA

Completed

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

Alzheimer Disease

United States, France, Japan, Australia, Germany
Bayer

Completed

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Atrial Fibrillation

Germany
Life Molecular Imaging SA

Completed

Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

Alzheimer Disease | Amyloid Beta-Protein

Australia
Life Molecular Imaging SA

Completed

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

Down Syndrome | Amyloid Beta-protein

United States
Novo Nordisk A/S

Completed

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

Obesity

United States
Novo Nordisk A/S

Completed

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Obesity

Japan
Beta Pharma Shanghai

Completed

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

NSCLC

China
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Pharmacokinetics

Germany
Bayer

Recruiting

A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Chronic Kidney Disease

India
Bayer

Recruiting

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Germany, Argentina, Belgium, Brazil, Canada, Chile, Colombia, France, Italy, Korea, Republic of, Luxembourg, Mexico, Netherlands, Russian Federation, Saudi Arabia, Singapore, Slovenia, Spain, Switzerland, Taiwan, Th... and more
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD)

Chronic Kidney Disease

Belgium, Finland, France, China, Hong Kong, Switzerland, United States, Turkey, Greece, New Zealand, Poland, South Africa, Spain, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, ... and more
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR) (DeFineDR)

Diabetic Retinopathy

United Kingdom, Bulgaria
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)

Diabetic Kidney Disease

Belgium, Finland, France, Spain, China, Hong Kong, Switzerland, United States, Colombia, Turkey, Greece, New Zealand, Poland, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, Sweden, Austr... and more
Bayer

Terminated

BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE 1)

Acute Heart Failure

Israel, Italy, Japan, Switzerland, United States, Austria, Germany, Thailand, Romania, Slovenia, Croatia, Serbia, Russian Federation, Finland, Sweden, Poland, Slovakia
Bayer

Completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN)

Diabetic Nephropathies

Hong Kong, Australia, Spain, Portugal, United States, France, Canada, Netherlands, Austria, Finland, Poland, Taiwan, Hungary, Israel, Italy, South Africa, Sweden, Bulgaria, Germany, Denmark, Czechia, Korea, Republic of, Norway
Bayer

Terminated

A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE 2)

Acute Heart Failure

Belgium, France, Argentina, United States, Austria, Mexico, Germany, Philippines, Ireland
Bayer

Terminated

A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF) (COMPOSE EARLY)

Heart Failure | Heart Decompensation

Italy, United States, Germany, Spain, Japan, Canada, France, Hungary, Poland, South Africa, Korea, Republic of, Israel, Finland, United Kingdom, Ireland, Czech Republic
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Erythropoietic Protoporphyria (EPP)

United States
Beta Pharma Shanghai

Completed

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Bayer
Steigerwald Arzneimittelwerk GmbH

Completed

Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes

Moderate Depressive Episodes (Major Depression)
Bayer

Completed

Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles

Contraception

Russian Federation
Bayer

Active, not recruiting

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Non-diabetic Chronic Kidney Disease

Hong Kong, United States, Spain, China, Belgium, Taiwan, Australia, Korea, Republic of, Russian Federation, United Kingdom, Singapore, Malaysia, Japan, Greece, Israel, Hungary, Italy, Czechia, Denmark, Argentina, Bulgaria, Mexico, I... and more
Bayer

Terminated

Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667

Congestive Heart Failure

Spain, Germany, Italy, United States, Canada, Hungary, Israel, Estonia, Slovenia, Croatia, Serbia, Lithuania, Poland, Sweden, Russian Federation, Czech Republic, United Kingdom
Life Molecular Imaging SA

Completed

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

Neoplasms

United States
Bayer

Completed

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants (FIGARO-BM)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Spain, Belgium, United States, Russian Federation, Hong Kong, Singapore, Taiwan, Korea, Republic of, Canada, Austria, Italy, Japan, Denmark, Australia, Bulgaria, Czechia, Finland, Israel, Netherlands, Sweden, Portugal
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

EPP | XLP

Spain, United States, Germany, Norway, Italy, Australia, Canada, Japan, Sweden, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
Welichem Biotech Inc.
Ozmosis Research Inc.

Completed

Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours

Solid Tumours

Canada
Bayer

Completed

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Oncology

United States
Bayer

Completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

Diabetic Nephropathies

Japan
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

Healthy Subjects

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Renal Impairment | Normal Renal Function

Germany
Mitsubishi Tanabe Pharma America Inc.

Active, not recruiting

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

EPP | XLP

United States, Germany, Japan, Spain, Italy, Sweden, Australia, Canada, Norway, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Mass Balance Study With MT-7117 (MT-7117 MB)

Healthy Volunteer

United Kingdom

3

Subscribe